Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation

British Journal of Cancer

Volumn 91, Issue 9, 2004, Pages 1735-1741

  Deutsch, E ^a   Maggiorella, L ^a   Wen, B ^a   Bonnet, M L ^a   Khanfir, K ^a   Frascogna, V ^a   Turhan, A G ^a   Bourhis, J ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

AKT; Bcr Abl; DNA PKcs; IGF1; Tyrosine kinase; Tyrphostin AG1024

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; BCR ABL PROTEIN; IMATINIB; JANUS KINASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; TYRPHOSTIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 9144223082     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602190     Document Type: Article

References (43)

1. Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG (2000) BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line. Oncogene 16: 489-496
2. Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19: 5574-5581
3. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, Akhatar AJ, Hilton J, Jones RJ (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86: 1148-1158
4. Bedi A, Zehmabauer BA, Barber JP, Sharkis SJ, Jones RJ (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83: 2038-2044
5. Benito A, Silva M, Grillot D, Nunez G, Fernandez-Luna JL (1996) Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Blood 87: 3837-3843
6. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H (1998) Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 7: 1661-1672
7. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Ab1 protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 1: 139-145
8. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104
9. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG (1998) BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 16: 335-348
10. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 12: 4947-4952
11. Cleveland JL, Dean M, Rosenberg N, Wang JY, Rapp UR (1989) Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol Cell Biol 9: 5685-5695
12. Coppola D, Ferber A, Miura M, Sell C, D'Ambrosio C, Rubin R, Baserga RA (1994) functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 14: 4588-4595
13. Cortez D, Kadlec DL, Pendergast AM (1995) Structural and signaling requirements for Bcr-Abl-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15: 5531-5541
14. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830
15. Deutsch E, Dugray A, AbdulKarim B, Marangoni E, Maggiorella L, Vaganay S, M'Kacher R, Rasy SD, Eschwege F, Vainchenker W, Turhan AG, Bourhis J (2001) BCR-ABL down regulates the DNA repair protein DNA-PKcs. Blood 97: 2084-2090
16. Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, Guilhot F, Turhan AG, Feunteun J, Bourhis J (2003) Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 101: 4583-4588
17. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 5: 561-566
18. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD (2000) BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem 275: 39223-39230
19. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932
20. Huettner CS, Zhang P, Van Etten RA, Tenen DG (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24: 57-60
21. Ilaria Jr RL, Van Etten RA (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271: 31704-31710
22. Issaad C, Ahmed M, Novault S, Bonnet ML, Bennardo T, Varet B, Vainchenker W, Turhan AG (2000) Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT7. Leukemia 14: 662-670
23. Komatsu N, Kirito K, Shimizu R, Kunitama M, Yamada M, Uchida M, Takatoku M, Raitano A, Whang YE, Sawyers CL (1997) Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta 1333: 201-216
24. Konopka JB, Witte ON (1985) Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 11: 3116-3123
25. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ (2002) In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30: 729-737
26. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082
27. Mandanas RA, Boswell HS, Lu L, Leibowitz D (1992) BCR/ABL confers growth factor independence upon a murine myeloid cell line. Leukemia 6: 796-800
28. McWhirter JR, Wang Jy (1991) Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 3: 1553-1565
29. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL (2000) The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 20: 1179-1186
30. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1330-1340
31. Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD (1994) Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 22: 1111-1117
32. Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM (2000) Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p 185 and p210 Bcr-Abl tyrosine kinases. Blood 9: 2913-2921
33. Raitano AB, Whang YE, Sawyers CL (1997) Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta 3: 201-216
34. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, Preudhomme C (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100: 1014-1018
35. Sanchez Garcia I, Grutz G (1995) Tumorigenic activity of the Bcr-Abl oncogene is mediated by Bcl-2. Proc Natl Acad Sci USA 92: 5287-5291
36. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90: 11217-11221
37. Skorski T, Kanakaraj P, Neiborowska-Skorska M, Ratajczakk MZ, Wen SC, Zon G, Gerrwitz AM, Perussia P, Calabretta B (1995) phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 2: 726-736
38. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T (2002) Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22: 4189-4201
39. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T (2001) BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8: 795-806
40. Steller MA, Zou Z, Schiller JT, Baserga R (1996) Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor. Cancer Res. 56: 5087-5091
41. Valentinis B, Baserga R (2001) IGF-I receptor signaling in transformation and differentiation. Mol Pathol. 54: 133-137
42. von Willebrand M, Zacksenhaus E, Cheng E, Glazer P, Ruth Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (1998) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145
43. Wen B, Deutsch E, Marangoni E, Frasona V, Maggiorella L, Abdulkarim B, Chavaudra N, Bourhis J (2001) Tyrphostin AG1024 modulates radio-sensitivity in human breast cancer cells. Br J Cancer 85: 2017-2021